BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$12.44 USD
-0.90 (-6.75%)
Updated Oct 29, 2025 04:00 PM ET
After-Market: $12.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCTX 12.44 -0.90(-6.75%)
Will BCTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for BCTX
Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding
Top 3 Earnings Acceleration Buys for November
BCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for BCTX
BCTX forms Bollinger Band Squeeze on October 28
Is BCTX set to breakout? Bollinger Band Squeeze shows up after dropping 2.68%
BCTX forms MACD Bullish Signal Line Cross on October 24
Is BCTX positioned for a breakout? Crossed Above 20 Day Moving Average shows up after surging 9.05%
Slingshot Bullish appears for BCTX after 5.64% move